糖心原创

• Print

Selected publications

• DURRANT LG, NOBLE P and SPENDLOVE I, 2012. . Clinical & Experimental Immunology. 167(2), 206-15
• FOX BA, SCHENDEL DJ, BUTTERFIELD LH, et al., 2011. . Journal Of Translational Medicine. 9(1), 214 (In Press.)
• DURRANT LG, PUDNEY VA and SPENDLOVE I, 2011. . Expert Review Of Vaccines. 10(7), 1093-106
• PUDNEY VA, METHERINGHAM RL, GUNN B, et al., 2010. . European Journal Of Immunology. 40(3), 899-910
• DURRANT LG, PUDNEY V, SPENDLOVE I, et al., 2010. . Expert Opinion On Biological Therapy. 10(5), 735-48
• METHERINGHAM RL, PUDNEY VA, GUNN B, et al., 2009. Antibodies Designed As Effective Cancer Vaccines. Mabs. 1(1), 71-85
• ULLENHAG GJ, SPENDLOVE I, WATSON NFS, et al., 2008. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Immunology. 128(2), 148-54
• DUNCAN TJ, WATSON NFS, AL-ATTAR AH, et al., 2007. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World Journal of Surgical Oncology. 5, 31
• CAPASSO M, DURRANT LG, STACEY M, et al., 2006. . The Journal of Immunology. 177(2), 1070-1077 
• DURRANT LG, HARDING SJ, GREEN NH, et al., 2006. . Cancer Research. 66(11), 5901-5909
• ULLENHAG GJ, SPENDLOVE I, WATSON NFS, et al., 2006. . Clinical Cancer Research. 12(24), 7389-7396
• PRITCHARD-JONES K, SPENDLOVE I, WILTON C, et al., 2005. . British Journal of Cancer. 92(8), 1358-1365
• PARSONS T, SPENDLOVE I, NIRULA R, et al., 2004. . Vaccine. VOL 22(NUMBER 25-26), 3487-3494
• DURRANT LG, PARSONS T, MOSS R, et al., 2001. . International Journal of Cancer. VOL 92(PART 3), 414-420